Product Sales

Full Year 2020 Product Sales

The following table provides the top 20 Innovative Medicines Division product net sales in 2020 as well as the change compared to 2019:

Brands Net Sales (USD m) % change (USD) Business Franchise
Cosentyx 3,995 13% Immunology, Hepatology and Dermatology
Gilenya 3,003 -7% Neuroscience
Entresto 2,497 45% Cardiovascular, Renal and Metabolism
Tasigna 1,958 4% Oncology
Lucentis 1,933 -7% Ophthalmology
Promacta/Revolade 1,738 23% Oncology
Tafinlar + Mekinist 1,542 15% Oncology
Sandostatin 1,439 -9% Oncology
Jakavi 1,339 20% Oncology
Xolair1 1,251 7% Respiratory
Galvus Group 1,199 -8% Established Medicines
Gleevec/Glivec 1,188 -6% Oncology
Afinitor/Votubia 1,083 -30% Oncology
Diovan Group 1,003 -6% Established Medicines
Exforge Group 980 -4% Established Medicines
Zolgensma 920 155% Neuroscience
Ilaris 873 30% Immunology, Hepatology and Dermatology
Kisqali 687 43% Oncology
Exjade/Jadenu 653 -33% Oncology
Votrient 635 -16% Oncology
Disclaimer

 

 

  1. Net sales reflect Xolair sales for all indications.